SOCS1 rs243330位点多态性与非酒精性脂肪性肝病的相关性研究
Study on Association between SOCS1 rs243330 Polymorphisms and Non-Alcoholic Fatty Liver Disease
摘要: 本文主要探究中国青岛地区人群细胞因子信号传导抑制因子1 (suppressors of cytkine signaling 1, SOCS1) rs243330位点多态性与非酒精性脂肪性肝病(non-alcoholic fatty liver disease, NAFLD)易感性的相关性。方法：纳入2022年06月~2023年06月青岛市市立医院收入院的NAFLD患者220例，健康对照者112例。提取受试者血液中的DNA，使用多聚酶链反应(polymerase chain reaction, PCR)的方法扩增DNA，并检测SOCS1基因rs243330位点的基因型。收集并分析患者的所有临床数据以及与代谢状态相关的指标。使用χ2检验分析基因型及等位基因频率。符合正态分布的计量资料采用t检验，不符合正态分布的计量资料采用Wilcoxon秩和检验进行组间比较。结果：NAFLD组和对照组SOCS1 rs243330位点的基因型与等位基因分布差异均无统计学意义。结论：在青岛地区人群中，SOCS1 rs243330位点多态性与NAFLD的无显著相关性。
Abstract: This study was aimed to explore the correlation between cytokine signaling inhibitor 1 rs243330 polymorphism and susceptibility to non-alcoholic fatty liver disease in Qingdao, China. Methods: 220 patients with NAFLD and 112 healthy controls admitted to Qingdao Municipal Hospital from June 2022 to June 2023 were included. DNA was extracted from the subjects’ blood, amplified by polymerase chain reaction (PCR), and genotype of SOCS1 gene rs243330 was detected. All clinical data of the patient and indicators related to metabolic status were collected and analyzed. Genotype and allele frequency were analyzed using χ2 test. T-test was used for measurement data conforming to normal distribution, and Wilcoxon rank sum test was used for comparison between groups for measurement data not conforming to normal distribution. Results: There were no significant differences in genotype and allele distribution of SOCS1 rs243330 between NAFLD group and control group. Conclusion: There is no significant correlation between SOCS1 rs243330 polymorphism and NAFLD in Qingdao population.
文章引用：崔禹, 赵真真. SOCS1 rs243330位点多态性与非酒精性脂肪性肝病的相关性研究[J]. 临床医学进展, 2024, 14(5): 352-360. https://doi.org/10.12677/acm.2024.1451434

参考文献

[1] Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[2] Nassir, F. (2022) NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12, Article No. 824. [Google Scholar] [CrossRef] [PubMed]
[3] Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142, 1592-1609. [Google Scholar] [CrossRef] [PubMed]
[4] Teli, M.R., James, O.F., Burt, A.D., et al. (1995) The Natural History of Nonalcoholic Fatty Liver: A Follow-Up Study. Hepatology, 22, 1714-1719. [Google Scholar] [CrossRef] [PubMed]
[5] Ekstedt, M., Hagström, H., Nasr, P., et al. (2015) Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD after up to 33 Years of Follow-Up. Hepatology, 61, 1547-1554. [Google Scholar] [CrossRef] [PubMed]
[6] Pais, R., Charlotte, F., Fedchuk, L., et al. (2013) A Systematic Review of Follow-Up Biopsies Reveals Disease Progression in Patients with Non-Alcoholic Fatty Liver. Journal of Hepatology, 59, 550-556. [Google Scholar] [CrossRef] [PubMed]
[7] Singh, S., Allen, A.M., Wang, Z., et al. (2015) Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 13, 643-654.E1-9. [Google Scholar] [CrossRef] [PubMed]
[8] Younossi, Z., Anstee, Q.M., Marietti, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. [Google Scholar] [CrossRef] [PubMed]
[9] Pais, R., Barritt, A.S.T., Calmus, Y., et al. (2016) NAFLD and Liver Transplantation: Current Burden and Expected Challenges. Journal of Hepatology, 65, 1245-1257. [Google Scholar] [CrossRef] [PubMed]
[10] Fitzmaurice, C., Abate, D., Abbasi, N., et al. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768. [Google Scholar] [CrossRef] [PubMed]
[11] Allen, A.M., Lazarus, J.V. and Younossi, Z.M. (2023) Healthcare and Socioeconomic Costs of NAFLD: A Global Framework to Navigate the Uncertainties. Journal of Hepatology, 79, 209-217. [Google Scholar] [CrossRef] [PubMed]
[12] Huh, Y., Cho, Y.J. and Nam, G.E. (2022) Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. Journal of Obesity & Metabolic Syndrome, 31, 17-27. [Google Scholar] [CrossRef] [PubMed]
[13] Fujimoto, M. and Naka, T. (2010) SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterology Research and Practice, 2010, Article ID: 470468. [Google Scholar] [CrossRef] [PubMed]
[14] Berntorp, E., Petrini, P., Dockter, G., et al. (2001) An Approach to Study the Viral Safety of Plasma-Derived Products in Previously Treated, Non-Infected Patients. Haemophilia, 7, 360-363. [Google Scholar] [CrossRef] [PubMed]
[15] Li, X., Liu, X., Tian, L., et al. (2016) Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clinical Reviews in Allergy & Immunology, 50, 41-54. [Google Scholar] [CrossRef] [PubMed]
[16] Galic, S., Sachithanandan, N., Kay, T.W., et al. (2014) Suppressor of Cytokine Signalling (SOCS) Proteins as Guardians of Inflammatory Responses Critical for Regulating Insulin Sensitivity. Biochemical Journal, 461, 177-188. [Google Scholar] [CrossRef] 
[17] Kempinska-Podhorodecka, A., Milkiewicz, M., Wasik, U., et al. (2017) Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-MiRNA155-SOCS1 Pathway. International Journal of Molecular Sciences, 18, Article No. 289. [Google Scholar] [CrossRef] [PubMed]
[18] Kang, I., Kim, J.A., Kim, J., et al. (2022) Hepatitis B Virus X Protein Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Regulating SOCS1. BMB Reports, 55, 220-225. [Google Scholar] [CrossRef] 
[19] Adams, L.A., Lymp, J.F., St Sauver, J., et al. (2005) The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology, 129, 113-121. [Google Scholar] [CrossRef] [PubMed]
[20] Eslam, M., Sanyal, A.J. and George, J. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158, 1999-2014.E1. [Google Scholar] [CrossRef] [PubMed]
[21] Ogden, C.L., Carroll, M.D., Kit, B.K., et al. (2014) Prevalence of Childhood and Adult Obesity in the United States, 2011-2012. JAMA, 311, 806-814. [Google Scholar] [CrossRef] [PubMed]
[22] Vernon, G., Baranova, A. and Younossi, Z.M. (2011) Systematic Review: The Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Adults. Alimentary Pharmacology & Therapeutics, 34, 274-285. [Google Scholar] [CrossRef] [PubMed]
[23] Loomba, R., Lim, J.K., Patton, H., et al. (2020) AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 158, 1822-1830. [Google Scholar] [CrossRef] [PubMed]
[24] Masuoka, H.C. and Chalasani, N. (2013) Nonalcoholic Fatty Liver Disease: An Emerging Threat to Obese and Diabetic Individuals. Annals of the New York Academy of Sciences, 1281, 106-122. [Google Scholar] [CrossRef] [PubMed]
[25] Almeida, E.A., Mehndiratta, M., Madhu, S.V., et al. (2022) Differential Expression of Suppressor of Cytokine Signaling and Interferon Gamma in Lean and Obese Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology and Metabolism, 20, E122553. [Google Scholar] [CrossRef] [PubMed]
[26] Feng, X., Tang, H., Leng, J., et al. (2014) Suppressors of Cytokine Signaling (SOCS) and Type 2 Diabetes. Molecular Biology Reports, 41, 2265-2274. [Google Scholar] [CrossRef] [PubMed]
[27] Xu, C.H., Liu, Y., Xiao, L.M., et al. (2019) Silencing MicroRNA-221/222 Cluster Suppresses Glioblastoma Angiogenesis by Suppressor of Cytokine Signaling-3-Dependent JAK/STAT Pathway. Journal of Cellular Physiology, 234, 22272-2284. [Google Scholar] [CrossRef] [PubMed]
[28] Doggett, K., Keating, N., Dehkhoda, F., et al. (2023) The SOCS1 KIR and SH2 Domain Are both Required for Suppression of Cytokine Signaling in Vivo. Cytokine, 165, Article ID: 156167. [Google Scholar] [CrossRef] [PubMed]
[29] Endo, T.A., Masuhara, M., Yokouchi, M., et al. (1997) A New Protein Containing an SH2 Domain That Inhibits JAK Kinases. Nature, 387, 921-924. [Google Scholar] [CrossRef] [PubMed]
[30] Chu, P.Y., Yeh, C.M., Hsu, N.C., et al. (2010) Epigenetic Alteration of the SOCS1 Gene in Hepatocellular Carcinoma. Swiss Medical Weekly, 140, W13065. [Google Scholar] [CrossRef] [PubMed]
[31] Okochi, O., Hibi, K., Sakai, M., et al. (2003) Methylation-Mediated Silencing of SOCS-1 Gene in Hepatocellular Carcinoma Derived from Cirrhosis. Clinical Cancer Research, 9, 5295-5298.
[32] Li, Z., Metze, D., Nashan, D., et al. (2004) Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma. Journal of Investigative Dermatology, 123, 737-745. [Google Scholar] [CrossRef] 
[33] Huang, F.J., Steeg, P.S., Price, J.E., et al. (2008) Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis. Cancer Research, 68, 9634-9642. [Google Scholar] [CrossRef] 
[34] Oshimo, Y., Kuraoka, K., Nakayama, H., et al. (2004) Epigenetic Inactivation of SOCS-1 by CpG Island Hypermethylation in Human Gastric Carcinoma. International Journal of Cancer, 112, 1003-1009. [Google Scholar] [CrossRef] [PubMed]
[35] Shao, N., Ma, G., Zhang, J., et al. (2018) MiR-221-5p Enhances Cell Proliferation and Metastasis through Post-Transcriptional Regulation of SOCS1 in Human Prostate Cancer. BMC Urology, 18, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[36] Davey, G.M., Starr, R., Cornish, A.L., et al. (2005) SOCS-1 Regulates IL-15-Driven Homeostatic Proliferation of Antigen-Naive CD8 T Cells, Limiting Their Autoimmune Potential. Journal of Experimental Medicine, 202, 1099-1108. [Google Scholar] [CrossRef] [PubMed]
[37] Alexander, W.S., Starr, R., Fenner, J.E., et al. (1999) SOCS1 Is a Critical Inhibitor of Interferon Gamma Signaling and Prevents the Potentially Fatal Neonatal Actions of This Cytokine. Cell, 98, 597-608. [Google Scholar] [CrossRef] 
[38] Chong, M.M., Cornish, A.L., Darwiche, R., et al. (2003) Suppressor of Cytokine Signaling-1 Is a Critical Regulator of Interleukin-7-Dependent CD8 T Cell Differentiation. Immunity, 18, 475-487. [Google Scholar] [CrossRef] 
[39] Starr, R., Metcalf, D., Elefanty, A.G., et al. (1998) Liver Degeneration and Lymphoid Deficiencies in Mice Lacking Suppressor of Cytokine Signaling-1. Proceedings of the National Academy of Sciences of the United States of America, 95, 14395-14399. [Google Scholar] [CrossRef] [PubMed]
[40] Gylvin, T., Ek, J., Nolsøe, R., et al. (2009) Functional SOCS1 Polymorphisms Are Associated with Variation in Obesity in Whites. Diabetes, Obesity and Metabolism, 11, 196-203. [Google Scholar] [CrossRef] [PubMed]
[41] Kempinska-Podhorodecka, A., Wunsch, E., Milkiewicz, P., et al. (2019) The Association Between SOCS1-1656G > A Polymorphism, Insulin Resistance and Obesity in Nonalcoholic Fatty Liver Disease (NAFLD) Patients. Journal of Clinical Medicine, 8, Article No. 1912. [Google Scholar] [CrossRef] [PubMed]

为你推荐